| 8.0022 0.512 (6.84%) | 03-10 11:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.27  |
1-year : | 10.83 |
| Resists | First : | 7.94 |
Second : | 9.27 |
| Pivot price | 7.12 |
|||
| Supports | First : | 6.91 |
Second : | 6.28 |
| MAs | MA(5) : | 7.38 |
MA(20) : | 7.01 |
| MA(100) : | 8.51  |
MA(250) : | 12.09 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 83.4 |
D(3) : | 68.8 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 20 | Low : | 6.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TLX ] has closed below upper band by 2.2%. Bollinger Bands are 5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.52 - 7.56 | 7.56 - 7.6 |
| Low: | 7.14 - 7.18 | 7.18 - 7.23 |
| Close: | 7.42 - 7.5 | 7.5 - 7.57 |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Tue, 10 Mar 2026
Telix Pharmaceuticals Limited Achieves Primary Objectives In Prostact Global Phase 3 Study Part 1 - marketscreener.com
Mon, 09 Mar 2026
Telix Pharma jumps on positive Phase 3 prostate cancer trial results - Investing.com
Mon, 09 Mar 2026
Telix prostate cancer drug trial meets safety goals - Investing.com
Mon, 09 Mar 2026
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives - GlobeNewswire
Mon, 09 Mar 2026
Early trial of Telix prostate cancer therapy shows manageable side effects - Stock Titan
Sat, 07 Mar 2026
Telix Pharmaceuticals (NASDAQ:TLX) Upgraded at Wall Street Zen - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 339 (M) |
| Shares Float | 273 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 225 (K) |
| Shares Short P.Month | 176 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.23 |
| Profit Margin | -0.9 % |
| Operating Margin | 1.9 % |
| Return on Assets (ttm) | 1.1 % |
| Return on Equity (ttm) | -1.9 % |
| Qtrly Rev. Growth | 49.2 % |
| Gross Profit (p.s.) | 1.12 |
| Sales Per Share | 2.37 |
| EBITDA (p.s.) | 0.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -396.5 |
| PEG Ratio | 0 |
| Price to Book value | 6.44 |
| Price to Sales | 3.34 |
| Price to Cash Flow | -155.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|